DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Denmark ONLY.

Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)

NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, and as a booster dose approximately 6 months after the second dose in individuals 18 years of age and older.

Report an Adverse Event (AE)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Denmark.

Lægemiddelstyrelsen
Axel Heides Gade 1
DK-2300 København S
Websted: www.meldenbivirkning.dk

Contact Us

Tel: +45 89 87 26 10
09:00 - 17:00
Monday - Friday